Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer

Acquired resistance to targeted cancer therapy is a significant clinical challenge. In parallel with clinical trials combining CDK4/6 inhibitors to treat HER2+ breast cancer, we sought to prospectively model tumor evolution in response to this regimen in vivo and identify a clinically actionable str...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qingfei, Guldner, Ian H., Golomb, Samantha M., Sun, Longhua, Harris, Jack A., Lu, Xin, Zhang, Siyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707314/
https://www.ncbi.nlm.nih.gov/pubmed/31444334
http://dx.doi.org/10.1038/s41467-019-11729-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707314/
https://www.ncbi.nlm.nih.gov/pubmed/31444334
http://dx.doi.org/10.1038/s41467-019-11729-1

Ejemplares similares